Oscar Health Inc
$ 15.63
0.26%
16 Apr - close price
- Market Cap 4,641,891,000 USD
- Current Price $ 15.63
- High / Low $ 15.93 / 15.43
- Stock P/E N/A
- Book Value 3.29
- EPS -1.72
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.44 %
- 52 Week High 23.80
- 52 Week Low 10.69
About
Oscar Health, Inc. offers health insurance products and services to individuals, families, and businesses in the United States. The company is headquartered in New York, New York.
Analyst Target Price
$15.40
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-10 | 2025-11-06 | 2025-08-06 | 2025-05-07 | 2025-02-04 | 2024-11-07 | 2024-08-07 | 2024-05-07 | 2024-02-07 | 2023-11-07 | 2023-08-08 | 2023-05-09 |
| Reported EPS | -1.24 | -0.53 | -0.89 | 0.92 | -0.62 | -0.22 | 0.2 | 0.62 | -0.66 | -0.29 | -0.07 | -0.18 |
| Estimated EPS | -0.92 | -0.5 | -0.89 | 0.81 | -0.58 | -0.18 | 0.16 | 0.27 | -0.7 | -0.47 | -0.16 | -0.09 |
| Surprise | -0.32 | -0.03 | 0 | 0.11 | -0.04 | -0.04 | 0.04 | 0.35 | 0.04 | 0.18 | 0.09 | -0.09 |
| Surprise Percentage | -34.7826% | -6% | 0% | 13.5802% | -6.8966% | -22.2222% | 25% | 129.6296% | 5.7143% | 38.2979% | 56.25% | -100% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.21 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OSCR
2026-04-13 20:09:52
Oscar Health director Sid Sankaran was granted 1,203 deferred stock units (DSUs) as compensation for board service, in lieu of cash payments. These DSUs, valued at $14.54 per share based on the April 9, 2026 closing price, are 100% vested on the grant date. They will be settled in cash or Class A shares at the company's discretion within 45 days after specific events like termination of service or a change in control.
2026-04-13 20:09:52
Oscar Health director William Gassen received 1,418 deferred stock units as compensation for his board service. These units, valued at $14.54 per share based on the April 9, 2026 closing price, bring his total holdings to 6,387 deferred units. This transaction represents equity-based compensation in lieu of cash, with settlement contingent on specified service-ending events.
2026-04-13 20:09:52
Oscar Health director Jeffery H. Boyd received a grant of 3,610 deferred stock units as compensation for his board service, valued at $14.54 per unit based on the closing share price on April 9, 2026. These units are granted in lieu of cash retainer payments under the company’s deferred compensation plan for directors. Following this transaction, Boyd directly holds 69,858 deferred stock units, which will be settled in cash or shares by Oscar Health's discretion after specific events.
2026-04-10 06:40:11
OSCAR HEALTH INC - CLASS A (BIT:1OSCR) stock closed at 12.57 EUR, up 7.44% on April 9, 2026. The company reported missed EPS and revenue expectations in Q4 2025, but analysts forecast significant growth in EPS (132.83%) and revenue (56.29%) for the next year. ChartMill assigned technical and fundamental ratings of 1/10 and 4/10 respectively, citing concerns about profitability despite average financial health.
2026-04-09 07:38:52
Oscar Health (OSCR) has attracted renewed investor interest due to 41.2% annual revenue growth and improved adjusted operating profits driven by efficiency gains. Despite recent share price pullbacks, longer-term shareholders have seen strong returns. The company is considered undervalued by some analysts, with a fair value of $15.40 against a closing price of $12.97, supported by substantial capital reserves and low leverage, though potential risks like higher claims costs in the ACA market exist.
2026-04-08 18:39:20
Mark T. Bertolini, CEO of Oscar Health (NASDAQ:OSCR), recently purchased 1,000,000 shares for $11.92 million, while also disposing of a similar number of shares to cover tax obligations. Despite the stock rising 11% since the purchase, the company recently reported wider-than-expected Q4 2025 losses, though Raymond James upgraded its rating to Outperform with an $18 price target, citing attractive valuation as margins recover.
